February 06, 2023

Unravelling lentigo maligna

48 minutes

Lentigo maligna – a subtype of in situ melanoma – presents diagnostic and treatment challenges for clinicians.

In this podcast, Dr Michael Rtshiladze leads a multidisciplinary discussion to unravel our understanding of the pathology, diagnosis and management of lentigo maligna, including:

clinical and histological presentation

tools to diagnose and monitor lesions

the impact of different types of biopsies

the importance of mapping the extent of lesions

the challenge of surgical management in cosmetically sensitive areas

the role of radiation therapy and topical treatments

when to refer your patient.

The discussion concludes with a case study to summarise key learnings.

This podcast is suitable for Plastic Surgeons, General Surgeons, Dermatologists, Oncologists, Pathologists, GPs, Nurses and other healthcare professionals.

SPEAKERS

Dr Michael Rtshiladze - Plastic and Reconstructive Surgeon, Melanoma Institute Australia, Royal Prince Alfred Hospital, The Prince of Wales Hospital, St George Hospital and Sydney Children’s Hospital

Dr Robert Rawson - Pathologist, Melanoma Institute Australia and Royal Prince Alfred Hospital

Prof Pascale Guitera - Dermatologist, Melanoma Institute Australia | Director, Sydney Melanoma Diagnostic Centre at Royal Prince Alfred Hospital | Professorial Research Fellow, The University of Sydney

Prof Angela Hong - Radiation Oncologist, Melanoma Institute Australia | Clinical Professor, The University of Sydney

RESOURCE AND REFERENCE

Lentigo Maligna Patient Information Brochure

Crouch G, Sinha S, Lo S, Saw RPM, Lee KK, Stretch J, Shannon K, Guitera P, Scolyer RA, Thompson JF & Ch'ng S. Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. Eur J Surg Oncol. 2021 May;47(5):1145-1151.

Please note that this podcast was accurate at the time of recording (December 2022) but may not reflect the rapidly evolving treatment landscape and approvals in Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from MSD, Bristol Myers Squibb and HEINE.

...more

View all episodes

By Melanoma Institute Australia

4.3

33 ratings